Obinutuzumab (GA101) in patients with relapsed/Refractory indolent non-hodgkin lymphoma: Results from the phase II GAUGUIN study

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages 2920-2926

  Salles, Gilles A ^a   Morschhauser, Franck ^b   Solal Céligny, Philippe ^c   Thieblemont, Catherine ^d   Lamy, Thierry ^e   Tilly, Hervé ^f   Gyan, Emmanuel ^g   Lei, Guiyuan ⁱ   Wenger, Michael ^j   Wassner Fritsch, Elisabeth ^j   Cartron, Guillaume ^h  

^a HOSPICES CIVILS DE LYON   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Cancérologie de l'Ouest Institute   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE ROUEN   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; IBRITUMOMAB TIUXETAN; OBINUTUZUMAB; PARACETAMOL; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HEPATITIS B; HUMAN; INFUSION RELATED REACTION; KIDNEY FAILURE; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; STEADY STATE; SUICIDE ATTEMPT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LYMPHOMA, FOLLICULAR; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; LYMPHOMA, FOLLICULAR; MIDDLE AGED;

EID: 84891398531     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.9718     Document Type: Article

References (27)

1. Coiffier B, Lepage E, Brière J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002.
2. Marcus R, Imrie K, Solal-Céligny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008.
3. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advancedstage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005.
4. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824- 4831, 2008.
5. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010.
6. Robak T, Dmoszynska A, Solal-Céligny P, et al: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756-1765, 2010.
7. Salles G, Seymour JF, Offner F: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011.
8. van Oers MH, Van Glabbeke M, Giurgea L, et al: Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Longterm outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28:2853- 2858, 2010.
9. Glennie MJ, French RR, Cragg MS, et al: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44:3823-3837, 2007.
10. Chan HT, Hughes D, French RR, et al: CD20- induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 63:5480- 5489, 2003.
11. Cragg MS, Glennie MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103:2738-2743, 2004.
12. Alduaij W, Ivanov A, Honeychurch J, et al: Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actindependent, lysosome-mediated cell death in B-cell malignancies. Blood 117:4519-4529, 2011.
13. Morschhauser F, Leonard JP, Fayad L, et al: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. J Clin Oncol 27:3346-3353, 2009.
14. Morschhauser F, Marlton P, Vitolo U, et al: Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 21:1870-1876, 2010.
15. Hagenbeek A, Gadeberg O, Johnson P, et al: First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase 1/2 trial. Blood 111:5486-5495, 2008.
16. Mossner E, Brunker P, Moser S, et al: Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity. Blood 115:4393-4402, 2010.
17. Herter S, Waldhauer I, Otz T, et al: Superior efficacy of the novel type II, glycoengineered CD20 antibody GA101 vs. the type I CD20 antibodies rituximab and of atumumab. Blood 116, 2010 (abstr 3925).
18. Sehn LH, Assouline SE, Stewart DA, et al: A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 119:5118- 5125, 2012.
19. Salles G, Morschhauser F, Lamy T, et al: Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119:5126-5132, 2012.
20. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999.
21. Davis TA, Grillo-Ló pez AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-Treatment. J Clin Oncol 18:3135-3143, 2000.
22. Coiffier B, Osmanov EA, Hong X, et al: Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximabsensitive, follicular lymphoma: A randomised phase 3 trial. Lancet Oncol 12:773-784, 2011.
23. Czuczman MS, Fayad L, Delwail V, et al: Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: Results from a multicenter study. Blood 119:3698-3704, 2012.
24. Morschhauser F, Salles G, Cartron G, et al: Dose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101): A rational approach. Haematologica 96, 2011 (suppl 2; abstr 0935).
25. Cartron GC, Morschhauser F, Thieblemont C, et al: Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed/refractory chronic lymphocytic leukemia (CLL). Haematologica 96, 2011 (suppl 2; abstr 0101).
26. Cartron G, Thieblemont C, Solal-Celigny P, et al: Results from a phase II study (BO20999) of RO5072759 (GA101) monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 22:4131-4132, 2011 (suppl 4; abstr 144).
27. Radford J, Davies A, Cartron G, et al: Obinutuzumab (GA101) in combination with FC or CHOP in patients with relapsed or refractory follicular lymphoma: Final results of the phase I GAUDI study (BO21000). Blood 118, 2011 (abstr 270).